UPDATE: Despite intervention from the Health Secretary and a new round of talks between the drug companies and NHS England, we were informed on 19 November that NICE, NHS England, Daiichi Sankyo and AstraZeneca had failed to find a way forward to make Enhertu available.
This means NICE’s final guidance, originally published on 29 July, not to recommend Enhertu for use on the NHS in England for women with HER2-low secondary breast cancer remains in place. As Wales and Northern Ireland follow NICE guidance, women there will miss out too.
We’re sorry that we haven’t yet brought about the result we all wanted to see, but you can still sign our petition to show NICE, NHS England, and the drug companies that Enhertu needs to be made available on the NHS, across the UK.
We’re facing an emergency, and we urgently need your help.
Enhertu, a life-extending drug for certain women with incurable HER2-low secondary breast cancer, has been rejected for use on the NHS in England.
This means thousands of women will be denied access to a drug that could’ve given them the hope of more time to live.
But you can help us change this.
Join our call on NICE, NHS England and the drug companies Daiichi Sankyo and AstraZeneca, to do everything possible to find a solution that makes Enhertu available on the NHS.
Time is against us. We need to act now. Please sign and share our petition. Help give these women back their hope.